Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.17 billion. The enterprise value is $4.14 billion.
| Market Cap | 3.17B |
| Enterprise Value | 4.14B |
Important Dates
The last earnings date was Thursday, February 6, 2025, before market open.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 50.24 million shares outstanding. The number of shares has decreased by -0.27% in one year.
| Current Share Class | 50.24M |
| Shares Outstanding | 50.24M |
| Shares Change (YoY) | -0.27% |
| Shares Change (QoQ) | -1.17% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 111.43% |
| Float | 49.73M |
Valuation Ratios
The trailing PE ratio is 24.82 and the forward PE ratio is 13.03. Haemonetics's PEG ratio is 1.03.
| PE Ratio | 24.82 |
| Forward PE | 13.03 |
| PS Ratio | 2.33 |
| Forward PS | 2.36 |
| PB Ratio | 3.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 38.02 |
| P/OCF Ratio | 24.50 |
| PEG Ratio | 1.03 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.95, with an EV/FCF ratio of 49.67.
| EV / Earnings | 31.81 |
| EV / Sales | 3.01 |
| EV / EBITDA | 11.95 |
| EV / EBIT | 17.26 |
| EV / FCF | 49.67 |
Financial Position
The company has a current ratio of 3.97, with a Debt / Equity ratio of 1.43.
| Current Ratio | 3.97 |
| Quick Ratio | 2.11 |
| Debt / Equity | 1.43 |
| Debt / EBITDA | 3.63 |
| Debt / FCF | 15.53 |
| Interest Coverage | 9.51 |
Financial Efficiency
Return on equity (ROE) is 14.06% and return on invested capital (ROIC) is 7.46%.
| Return on Equity (ROE) | 14.06% |
| Return on Assets (ROA) | 6.33% |
| Return on Invested Capital (ROIC) | 7.46% |
| Return on Capital Employed (ROCE) | 10.52% |
| Revenue Per Employee | $375,585 |
| Profits Per Employee | $35,566 |
| Employee Count | 3,657 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, Haemonetics has paid $34.68 million in taxes.
| Income Tax | 34.68M |
| Effective Tax Rate | 21.05% |
Stock Price Statistics
The stock price has decreased by -11.77% in the last 52 weeks. The beta is 0.39, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -11.77% |
| 50-Day Moving Average | 73.12 |
| 200-Day Moving Average | 80.33 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 1,382,066 |
Short Selling Information
The latest short interest is 5.24 million, so 10.44% of the outstanding shares have been sold short.
| Short Interest | 5.24M |
| Short Previous Month | 5.23M |
| Short % of Shares Out | 10.44% |
| Short % of Float | 10.54% |
| Short Ratio (days to cover) | 7.94 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.37 billion and earned $130.07 million in profits. Earnings per share was $2.54.
| Revenue | 1.37B |
| Gross Profit | 768.33M |
| Operating Income | 239.64M |
| Pretax Income | 146.99M |
| Net Income | 130.07M |
| EBITDA | 346.06M |
| EBIT | 239.64M |
| Earnings Per Share (EPS) | $2.54 |
Balance Sheet
The company has $322.58 million in cash and $1.29 billion in debt, giving a net cash position of -$970.82 million or -$19.32 per share.
| Cash & Cash Equivalents | 322.58M |
| Total Debt | 1.29B |
| Net Cash | -970.82M |
| Net Cash Per Share | -$19.32 |
| Equity (Book Value) | 906.86M |
| Book Value Per Share | 18.05 |
| Working Capital | 752.64M |
Cash Flow
In the last 12 months, operating cash flow was $129.25 million and capital expenditures -$45.97 million, giving a free cash flow of $83.28 million.
| Operating Cash Flow | 129.25M |
| Capital Expenditures | -45.97M |
| Free Cash Flow | 83.28M |
| FCF Per Share | $1.66 |
Margins
Gross margin is 55.94%, with operating and profit margins of 17.45% and 9.47%.
| Gross Margin | 55.94% |
| Operating Margin | 17.45% |
| Pretax Margin | 11.99% |
| Profit Margin | 9.47% |
| EBITDA Margin | 25.19% |
| EBIT Margin | 17.45% |
| FCF Margin | 6.06% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.27% |
| Shareholder Yield | 0.27% |
| Earnings Yield | 4.11% |
| FCF Yield | 2.63% |
Analyst Forecast
The average price target for Haemonetics is $103.56, which is 64.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $103.56 |
| Price Target Difference | 64.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 8.77% |
| EPS Growth Forecast (5Y) | 35.09% |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.97 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.97 |
| Piotroski F-Score | 5 |